4-2-07

Please type a plus sign (+) inside this box →

Tru)

PTO/SB/21 (05-03).

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/551,847 **Application Number** Filing Date June 23, 2006 TRANSMITTAL First Named Inventor HAIXIANG, LIN FORM **Group Art Unit** Unassigned (to be used for all correspondence after initial filing) **Examiner Name** Unassigned Attorney Docket Number **NBMP-001** Total Number of Pages in This Submission ENCLOSURES (check all that apply) Fee Transmittal Form **Assignment Papers** After Allowance Communication (for an Application) to Group Fee Attached Drawing(s) Appeal Communication to Board of Appeals and Interferences Amendment / Reply Licensing-related Papers After Final Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Affidavits/declaration(s) **Proprietary Information** Petition to Convert to a Extension of Time Request **Provisional Application** Status Letter **Express Abandonment Request** Power of Attorney, Revocation Change of Correspondence Information Disclosure Statement Other Enclosure(s) (please Address identify below): Terminal Disclaimer Certified Copy of Priority • SB08A Form (2 pgs.) **Documents** • 10 References Request for Refund International Search Reports (7 pgs.) Response to Missing Parts/ Return Postcard Incomplete Application CD, Number of CD(s Response to Missing Parts Remarks under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signing Attorney/Agent CAROL L. FRANCIS, PH.D., 36,513 (Reg. No.) BOZICEVIC, FIELD & FRANCIS, LLP Signature March 30, 2007 Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV 954 013 452 US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## Express Mail No. EV 954 013 452 US

INFORMATION	Attorney Docket	NBMP-001
DISCLOSURE STATEMENT	First Named Inventor	HAIXIANG, LIN
	Application Number	10/551,847
	Confirmation No.	6184
	Filing Date	June 23, 2006
Address to:	Group Art Unit	Unassigned
Mail Stop  Commissioner for Patents	Examiner Name	Unassigned
P.O. Box 1450 Alexandria, VA 22313-1450	Title: "POLYINOSINIC ACID-POLYCYTIDYLIC ACII BASED ADJUVANT"	

Sir:

4

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

Copies of the International Search Reports for the following PCT applications are enclosed for the Examiner's consideration:

- PCT/SG2006/000177
- PCT/CN2005/000810

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. NBMP-001 may be charged thereon.

Respectfully submitted,

BOZICEVIC FIELD & FRANCIS LI

By:

Carol L. Francis, Ph.D. Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/551,847 **Application Number** MAR 3 0 200 INFORMATION DISCLOSURE Filing Date June 23, 2006 STATEMENT BY APPLICANT First Named Inventor HAIXIANG, LIN Art Unit Unassigned **Examiner Name** Unassigned (use as many sheets as necessary) 2 **Attorney Docket Number NBMP-001** Sheet

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	
		US- 3,952,097	04-20-1976	Levy	
		US- 4,024,241	05-17-1977	Levy	
		US- 4,140,761	02-20-1979	Gerin et al.	
		US- 4,349,538	09-14-1982	Levy	
		US- 4,389,395	06-21-1983	Lerner et al.	
		US- 4,954,298	09-04-1990	Yamamoto et al.	
		US- 6,468,558	10-22-2002	Wong	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Foreign Patent Document  Country Code3-Number4-Kind Code 5(if known)	Publication Date -MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
-		JP 1186818	07-26-1989	YAMASA SHOYU KK; TOA EIYO LTD			
		JP 57002220	01-07-1982	TORAY INDUSTRIES			
		WO 2005/014038	02-17-2005	THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY			
		EP 0025766A3	03-25-1981	MERCK & CO.			
		EP 0025766A2	03-25-1981	MERCK & CO.			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		HOUSTON et al. "Modified Polyriboinosinic-Polyribocytidylic Acid, an Immunological Adjuvant," Infection and Immunity, American Society for Microbiology, July 1976, Vol. 14(1) p. 318-319.			
		KENDE et al. "Enhanced Therapeutic Efficacy of Poly(ICLC) and Ribavirin Combinations against Rift Valley Fever Virus Infection in Mice," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, July 1987, Vol. 31(7) p. 986-990.			
		LAKE et al. Involvement of protein kinase C in macrophages activation by poly (C). American Journal of Physiology (1994) vol. 266(1) pp. C134-42.			

Examiner	 Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/551,847	
INFORMATION DISCLOSURE			SURE	Filing Date	June 23, 2006	
	STATEMENT BY APPLICANT			First Named Inventor	HAIXIANG, LIN	
				Art Unit	Unassigned	
(use as many sheets as necessary)			y)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	NBMP-001	

NON PATENT LITERATURE DOCUMENTS				
	LEVY et al. "Immune Modulating Effects of Poly ICLC," Annals New York Academy of Sci p.33-41.	ences, 1980,		
	LIN et al. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral a effects. Archives of Virology (1993) col. 131: pp. 307-319.	and adjuvant		
		:		
		·		
Examiner Signature	Date Considered			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.